Speaker(s): 

Rosa Roman, MD-Pediatric Resident, Geisinger-has nothing to disclose.

Bryn Griffith, DO-Pediatric Resident, Geisinger-has nothing to disclose.

Moderator(s): 

Frank Maffei, MD, Chair, Pediatrics, JWCH, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Define Neonatal Abstinence Syndrome (NAS)/Neonatal Opioid Withdrawal Syndrome (NOWS) and describe the constellation of symptoms.
• Review the history and epidemiology and summarize health care costs associated with NOWS.
• Explain the pathophysiology of opioid withdrawal.
• Describe the current approach to evaluation of infants with NOWS and discuss limitations.
• Contrast nonpharmacologic and pharmacologic management strategies for infants being observed for NOWS.
• Analyze growth trends in the neonatal period for infants affected by NOWS.
• Review current nutritional management strategies for infants being observed for NOW.
• Discuss current research at Geisinger JWCH newborn nursery on nutritional management for neonates being observed for NOWS.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Frank Maffei, MD; Sarah Marks, MD; Amy Diehl, BSN, RN, CPN; Joan Keehan, RPH; Sandra Heller and Connie Winter have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant. 

Commercial Support for this Session

None